broadly neutralizing antibody (bNAb, VRC01)

^[1]^[2]^[3]

Notes

genes for broadly neutralizing antibodies may be inserted into an adenovirus vector for use in vectored immunoprophylaxis
VRC01 (10 or 30 mg/kg) decreased acquisition of antibody-sensitive HIV1 by 75%, but did not prevent infection with nonsusceptible HIV1^[2]
broadly neutralizing antibodies that neutralize all coronaviruses by targeting surface antigens common to all coronaviruses^[3]

* VRC01 is a preparation of broadly neutralizing antibodies

↑ Balazs AB et al. Vectored immunoprophylaxis protects humanized mice from mucosal HIV transmission. Nat Med 2014 Mar; 20:296. PMID: https://www.ncbi.nlm.nih.gov/pubmed/24509526
Corey L and McElrath MJ. One shot forward for HIV prevention. Nat Med 2014 Mar 4; 20:241 PMID: https://www.ncbi.nlm.nih.gov/pubmed/24603794
↑ ^2.0 ^2.1 Corey L et al. Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition. N Engl J Med 2021 Mar 18; 384:1003. PMID: https://www.ncbi.nlm.nih.gov/pubmed/33730454 https://www.nejm.org/doi/10.1056/NEJMoa2031738
↑ ^3.0 ^3.1 Tortorici MA, Czudnochowski N, Starr TN et al. Broad sarbecovirus neutralization by a human monoclonal antibody. Nature 2021 Sep 2; 597:103 PMID: https://www.ncbi.nlm.nih.gov/pubmed/34280951 https://www.nature.com/articles/s41586-021-03817-4
Pinto D, Sauer MM, Czudnochowski N et al. Broad betacoronavirus neutralization by a stem helix-pecific human antibody. Science 2021. Sep 3; 373:1109. PMID: https://www.ncbi.nlm.nih.gov/pubmed/34344823 https://www.science.org/doi/10.1126/science.abj3321
Martinez DR, Schafer A, Globeil S et al A broadly cross-reactive antibody neutralizes and protects against sarbecovirus challenge in mice. Science Translational Medicine 2021. Nov 2. https://www.science.org/doi/10.1126/scitranslmed.abj7125